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ABSTRACT: We have used a chemically diverse panel of kinase inhibitors to
assess the chemical similarity of the ATP-binding sites of cyclin-dependent kinase
(CDK) subfamily members in a range of activation states. Using this approach, we
find that different activation states of a particular CDK may differ from each other
as much as different CDKs in the same activation state. We also find that
inhibitors discriminate more effectively among CDK family members in their
monomeric state than in their cyclin-bound state, providing direct evidence for
the belief that selective binding to inactive kinase states might be more readily
achieved than selective binding to active states.
Protein kinases represent attractive targets for therapeuticintervention against a wide variety of human diseases, most
notably cancer1,2 and chronic inflammatory diseases.3 A
number of drugs that selectively target the protein kinase
ATP binding site have been successfully introduced into the
clinic, and many more are in clinical trials.2,4 However, a
significant requirement for the further development of
therapeutically useful compounds is a more complete under-
standing of the factors that dictate inhibitor selectivity across
the protein kinase family.5,2,6
The eukaryotic serine/threonine and tyrosine protein kinase
family is characterized by a conserved fold in which residues
from both the N- and C-terminal lobes contribute to the active
site.7,8 The identities of the residues that line the ATP binding
pocket and the structural plasticity of the protein kinase fold
constitute two key elements that together determine the
inhibitor-binding profile of a protein kinase. Both of these
elements have been successfully exploited to generate clinically
useful drugs.1,2
The cyclin-dependent kinases (CDKs) constitute a subfamily
of ca. 13 members in humans9 that play important roles in both
the control of cell cycle progression (CDKs 1, 2, 3, 4, and 6)
and in the regulation of transcription (CDKs 7, 8, 9, 12, and
13).10−12 CDK2 has provided a structural paradigm for the
CDK family and has been widely exploited for structure-aided
CDK inhibitor design.13,14 The prevailing structural model for
CDK regulation by cyclin and CDK inhibitor (CKI) binding
and by phosphorylation has been elaborated through a series of
structures of CDK2/cyclin A complexes.15,16 Monomeric
CDK2 is inactive as a result of the disposition of active site
residues, in turn dependent on the pose of the C-helix, and the
conformation of the activation segment.17 Cyclin A binding and
Thr160 phosphorylation within the activation segment
rearrange the CDK2 active site to orientate key ATP binding
and catalytic residues and create the peptide substrate binding
site.15,18 This model for the mechanism of regulation appears
not to apply across the entire CDK subfamily. The
determination of structures for CDK4/cyclin D319 and
CDK4/cyclin D1 phosphorylated on Thr172 (pCDK4/D)20
revealed that CDK4 adopts an inactive C-helix out con-
formation despite being cyclin-bound. Two further examples
are CDK521 and CDK822 that both adopt active conformations
upon p25 and cyclin C binding, respectively, in the absence of
activation loop phosphorylation.
Differential scanning fluorimetry (DSF) can be used to
characterize inhibitor binding.23 Here we define ΔTm as the
difference between the apparent melting temperature (Tm) of
the protein in the presence of the ligand and the Tm of the
protein alone. The value is related to the concentration and
binding affinity of the ligand for the protein and to
thermodynamic properties of the ligand binding event.23 The
profile of ΔTm values measured for a protein in the presence of
a sufficiently diverse range of inhibitors is characteristic of the
inhibitor binding properties of that protein and therefore
represents a fingerprint of the physicochemical properties of the
active site.24 We have used such fingerprints to assess the
chemical similarity of a number of CDK subfamily members,
namely, CDK2, CDK4, CDK7, and CDK9. Additionally, we
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have explored the inhibitor binding profiles of CDKs in
different activation states to assess the extent to which CDK
activation affects inhibitor binding.
■ RESULTS AND DISCUSSION
The discriminative power of this fingerprinting approach relies
on including a sufficiently diverse panel of inhibitors to sense
the chemical diversity apparent in the family of kinase active
sites. To validate the use of our selected inhibitor set (Figure 1a
and Supplementary Table 1) for this purpose, we confirmed
that our set is able to target representative kinases from across
the kinome. This analysis was achieved by mapping each
inhibitor onto those kinases in the kinome phylogenetic tree
that they are best documented to target (Supplementary
Methods and Figure 1b). The approximately uniform
distribution obtained confirms ours to be a relatively unbiased
set of inhibitors.
We included four members of the CDK subfamily in the
study. CDK2 was prepared in four different conformational
states: monomeric unphosphorylated (CDK2), monomeric
phosphorylated on Thr160 (pCDK2), unphosphorylated in
complex with human cyclin A175−432 (CDK2/A), and Thr160-
phosphorylated in complex with human cyclin A175−432
(pCDK2/A). CDK4 was characterized both as an inactive,
nonphosphorylated monomer (CDK4) and as the fully
activated binary complex (CDK4/cyclin D3 phosphorylated
on Thr172, pCDK4/D). CDK7 and CDK9 were prepared in
either a monomeric unphosphorylated (CDK7) or a cyclin-
bound phosphorylated (CDK9/cyclin T1 phosphorylated on
T186, pCDK9/T) state, respectively (Figure 2a). The identities
of the CDKs together with their activation states define a search
Figure 1. Explored chemical space. (a) Representative inhibitor scaffolds. Examples of the inhibitor scaffolds included in the panel are shown. All
inhibitor structures are provided in the Supporting Information (Supplementary Table 1). (b) Chemical space explored by the panel of inhibitors
used in this study. The target(s) in the human kinome for each of the inhibitors of the panel are identified by a red rectangle on the kinome tree.
This figure was adapted from the phylogenetic tree published in ref 9.
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Figure 2. CDK space explored in this study. (a) Representative melting curves for cyclin-dependent kinase (CDK)/cyclin complexes used to derive
ΔTm values in the presence of an ATP-competitive inhibitor. The shift in Tm upon staurosporine binding (red) is illustrated for each of the CDK/
cyclin complexes in this study. Black curves, CDK/cyclin complexes in the absence of added inhibitor. Curves with closed triangle symbols
correspond to pCDK9/T, closed diamonds to CDK7, closed circles to CDK4, closed squares to pCDK4/D, open squares to CDK2/A, open
diamonds to CDK2, and open triangles to pCDK2. (b) The full set of different phosphorylated and/or cyclin-associated states of the four CDKs
characterized in this study are shown, with those members for which measurements were made highlighted by shaded boxes. Color intensity for
these protein species reflects activation state (more saturated, more active). (c) The ATP binding site of CDKs. The CDK2 ATP-binding site
residues from a pCDK2/A structure (PDB code: 1QMZ) are colored according to the degree of sequence conservation between the 4 CDK
sequences, calculated as described in the Supplementary Methods, from blue (highly conserved) to red (highly variable). The ATP molecule is
represented in ball-and-stick mode for context. (d) The ATP-binding site pocket is highly conserved in CDK2, CDK7, CDK4, and CDK9. Residues
that constitute the first shell of the CDK2 ATP-binding site (CDK2 numbering) were identified as defined in Supplementary Methods and used to
construct a pseudosequence alignment. This alignment is displayed together with the associated consensus sequence, with X representing any
residue, and ϕ a hydrophobic amino acid. Sequence motifs that are highly conserved across the protein kinase family are identified by numbered bars.
Bar 1, the glycine-rich loop (residues 11−16 in CDK2) that defines the general consensus sequence GXGXXG that recognizes the phosphate
moieties of ATP; bar 2, the “hinge” sequence composed of residues 80−84 that links the N- and C-terminal lobes and contributes to the ATP
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space within the functional kinome that has been explored by
this study and is summarized in Figure 2b. CDK2, CDK7,
CDK4, and CDK9 are highly homologous across their entire
sequence (Supplementary Figure 1), and this similarity is
particularly marked at the catalytic site (Figure 2c,d).
We have adopted the linear correlation coefficient of the
inhibitory profiles of two kinases as a measure of the chemical
similarity of those kinases (Tm values tabulated in Supple-
mentary Table 1, Supplementary Figure 2). By this criterion, we
find that the set of kinases studied in the monomeric,
unphosphorylated state (CDK2, CDK4, and CDK7) demon-
strate significantly different inhibitory profiles, with a lowest
correlation coefficient of 0.39 (CDK4 vs CDK7) and a highest
correlation coefficient of 0.74 (CDK2 vs CDK7) (Figure 3a).
That the inhibitor binding fingerprint discriminates so
effectively between highly related CDK subfamily members
confirms that it provides a sensitive measure of active site
similarity.
One application of this measure is to assess the chemical
similarity of the active sites of orthologous proteins from
different species. For example, the correlation coefficients
obtained for the comparison of human monomeric, unphos-
phorylated CDKs with the closest CDK orthologue from
Plasmodium falciparum, protein kinase 5 (PfPK5), range from
0.42 (PfPK5 vs CDK4) to 0.69 (PfPK5 vs CDK2). This result
demonstrates that the active sites of orthologous proteins from
highly diverged species may be more similar to each other than
are the active sites of close paralogues within a species.
For context, the equivalent comparison of each of the
monomeric, unphosphorylated CDKs with an “unrelated”
kinase, P. falciparum protein kinase 7 (PfPK7),25 yields
correlation coefficients in the range 0.33 (PfPK7 vs CDK2)
to 0.31 (PfPK7 vs CDK2/A).
Next we investigated the apparent active-site similarity of a
set of fully activated CDK subfamily members (pCDK2/A,
pCDK4/D, and pCDK9/T). Although this comparison also
yielded quantitatively different inhibitor fingerprints, our results
suggest that the inhibitor-binding properties of the set of fully
activated CDKs are more similar to each other than are those of
the set of inactive monomeric forms (Figure 3b). The lowest
correlation coefficient of 0.73 and the highest correlation
coefficient of 0.78 were measured for comparisons of pCDK2/
A vs pCDK9/T and pCDK2/A vs pCDK4/D, respectively.
This result has two implications: first, it demonstrates that the
inhibitor binding properties of CDK subfamily members
depend not only on their respective sequence but also on the
conformational state in which they are found. Second, it
demonstrates that, in adopting an active conformation, two
different CDKs assume more similar inhibitor binding proper-
ties. This latter point is most directly demonstrated by
comparison of the correlations coefficients CDK2 vs CDK4
(CC = 0.69) and pCDK2/A vs pCDK4/D (CC = 0.78).
The inhibitor fingerprints of four different CDK2 activation
states were recorded, and the resulting comparison is shown in
Figure 3c. As expected from comparative structural studies,26,27
phosphorylation of the activation segment has little effect on
the inhibitor-binding fingerprint (correlation coefficient for the
Figure 2. continued
adenine binding site; bar 3, the “DFG motif” that defines the start of the activation segment. Asterisks below E51 and D127 highlight the conserved
glutamate in the C-helix and the catalytic aspartate, respectively. A full sequence alignment is presented in Supplementary Figure 1.
Figure 3. Comparison of the inhibitor-binding profiles of various cyclin-dependent kinase (CDK) subfamily members in different states of activation.
Each block represents a CDK in a particular activation state: CDK (monomeric, unphosphorylated), pCDK (monomeric, phosphorylated), CDK/[A
or D or T] (unphosphorylated binary complex between a CDK and the corresponding cyclin), and pCDK/[A or D or T] (phosphorylated binary
complex between a CDK and the corresponding cyclin). The internal consistency of inhibitory fingerprints for each CDK/state pair, evaluated over
two or three repeat measurements, is indicated by a value within the corresponding block. The correlation of fingerprints between different CDK/
state pairs is indicated by a value on the line that connects them. (a) Comparison of the inhibitor fingerprints of CDK subfamily members in the
monomeric form. (b) Comparison of the inhibitor fingerprints of CDK subfamily members in the phosphorylated binary forms. (c) Comparison of
CDK2 inhibitor fingerprints in different activation states. Color intensity as in Figure 2b reflects activation state (more saturated, more active).
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comparison CDK2 vs pCDK2 is 0.94 and for the comparison of
CDK2/A vs pCDK2/A is 0.96). Indeed, sequence and
structural comparisons demonstrate that phosphorylation of
CDK2 or CDK2/A on Thr160 introduces only minor changes
to the identity and structure of the amino acids that line the
extended inhibitor binding site (Supplementary Figure 3).
By contrast, when pCDK2 associates with cyclin A, the
CDK2 inhibitor-binding fingerprint changes significantly
(correlation coefficient for pCDK2 vs pCDK2/A is 0.79).
Interestingly, the equivalent comparison for unphosphorylated
CDK2 demonstrates somewhat less of a response: when cyclin
A associates with the unphosphorylated form of CDK2, it
perturbs its inhibitor binding profile to a lesser extent
(correlation coefficient for CDK2 vs CDK2/A = 0.91).
Comparison of the ATP binding site topology highlights a
similar degree of conservation between the closest pairs
considered, as summarized in Supplementary Figure 3.
For the CDKs analyzed in this study, the abundance of each
conformational state within a cell will depend on a large
number of factors that include CDK identity, cell type, cell
environment, and cell cycle stage. Targeting a specific
conformation of a protein kinase is a validated route to the
design of selective and potent inhibitors and has been
particularly successful in the design of tyrosine kinase
inhibitors.28 Cell cycle CDKs of differing phosphorylation
status and in monomeric and cyclin-bound forms can be
detected in cells, suggesting that such states are accessible for
targeting.29
In summary, by using DSF we have demonstrated that it is
possible to discriminate between closely related CDKs by
comparing their inhibitor-binding profiles. We have shown that
activation state can have a significant effect on inhibitor-binding
profile, with cyclin binding having more profound consequen-
ces than phosphorylation at least in the case of CDK2. Our
results further suggest that the inhibitor binding properties of a
set of fully activated, cyclin-bound CDKs are more similar to
each other than are those of a set of inactive, monomeric forms.
These data provide direct evidence that, as has been proposed
elsewhere,13 protein kinases may be more amenable to selective
inhibitor binding in their inactive states.
■ METHODS
Inhibitor Set. A full description of the inhibitor set is provided in
the Supporting Information.
CDK Expression and Purification. Human CDK4 and cyclin
D3,19 CDK9 and cyclin T130 were all expressed in insect cells and
purified as described. CDK2 phosphorylated on Thr160 in association
with cyclin A2 (pCDK2/A),18 unphosphorylated CDK2 in association
with cyclin A2 (CDK2/A), monomeric Thr160pCDK2 (pCDK2),26
monomeric unphosphorylated CDK2 (CDK2), and CDK7 were
prepared as described.31 Monomeric CDK4 was expressed in Sf9 cells
as a GST fusion and purified by affinity chromatography followed by
3C cleavage of the GST tag and subsequent size-exclusion
chromatography. The proteins were concentrated to 2 mg mL−1 and
flash frozen in liquid nitrogen prior to storage at −80 °C until further
use.
Differential Scanning Fluorimetry. Thermal melting experi-
ments were carried out using an Mx3005p Real Time PCR machine
(Stratagene) essentially as described.32,33 A full description of the
method is provided in the Supporting Information.
Kinase Targets of the Molecules Contained in the Inhibitor
Set. The kinase targeted by each of the inhibitors was identified from
either the supplier’s information or by literature analysis, mainly via the
work reported in refs 34−36.
Computation. Residues corresponding to the first coordination
shell of the ATP-binding sites were identified in ref 37. Sequence
conservation scores were calculated using the ConSurf webserver
(http://consurf.tau.ac.il).
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